All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld MedTech Perspectives » 2015: Something new or the same old same old?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

2015: Something new or the same old same old?

Jan. 14, 2015
By Mark McCarty
No Comments

Will auld acquaintance be forgot? Not likely.
Will auld acquaintance be forgot? Not at all likely.

It’s a new year with a host of new possibilities, not to mention a few hangovers from 2014. So what will 2015 bring to the world of med tech? Let’s find out.

Administration says “revenue-neutral”

Will Rogers is credited with having said, “the only difference between death and taxes is that death doesn't get worse every time Congress meets.” This year might prove the exception where corporate tax reform is concerned. I say that because Secretary of Commerce Penny Pritzker is now on record as saying the Obama administration is on board with revenue-neutral tax reform (See Pritzker’s remarks at 2:45). That doesn’t mean tax reform is going to happen this year, but it’s not a bad start.

Incidentally, this might also be a signal to the Business Round Table and the U.S. Chamber of Commerce to get their member ducks in a row unless they’re prepared to wait until 2017 to start this whole thing all over again, and it’s not a slam-dunk that the 115th Congress will be more amenable to tax reform than the current Congress.

FDA and LDT regs: good idea or no?

It’s all a question of whose ox is getting gored, but the two-day FDA meeting on the agency’s proposal to regulate lab-developed tests was actually pretty interesting. One of the speakers was Girish Putcha, director of lab science at Palmetto GBA, which handles a lot of requests for diagnostic coverage on behalf of the Centers for Medicare & Medicaid Services.

Putcha said among other things that the statute does no rule out the possibility that CMS can require that a test be checked for clinical validation and instrument and software validation, but he advised FDA avoid asking too much for design controls and other such features of the quality systems regulations.

The common expectation is that FDA regulation of clinical labs will drive some tests out of labs, which of course will dry up some revenues. I have a problem choking down this business of citing the latest FDA-approved BRCA test by Myriad as an example of an LDT as at all suggestive of the future for labs, though. I strongly suspect Myriad paid the tab for that effort, not the lab.

There’s a saying that if you want less of something, tax it. Same goes for regulations. It’ll be interesting to see what the clinical lab business looks like five years from now.

Fun with comparative ineffectiveness

It’s always amusing to watch those who are unfamiliar with the world of med tech attempt to impose their will on this continually churning sector of life science. The January Journal of the American College of Cardiology offered a comparative effectiveness report on coronary artery bypass and PCI for stable ischemic heart disease, and the authors concluded that at four years or longer, patients undergoing bypass "had better outcomes but at higher costs than those undergoing PCI."

But as the song says, that’s [not] where the fun is. This study drew on Medicare data for patients treated between 2004 and 2008, and of course the data are obsolete. The authors said as much, remarking, that most interventionalists "now have at least four types of DES available," and thus the question facing policymakers now is whether these outcomes would hold "if second-generation DES were to be implanted" in such a population.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing